Ocera Therapeutics Inc. (NASDAQ:OCRX) shares saw unusually-high trading volume on Friday . Approximately 77,347 shares changed hands during mid-day trading, an increase of 48% from the previous session’s volume of 52,183 shares.The stock last traded at $2.59 and had previously closed at $2.53.

OCRX has been the topic of several analyst reports. Zacks Investment Research cut Ocera Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 10th. Brean Capital restated a “buy” rating on shares of Ocera Therapeutics in a research note on Tuesday, April 12th.

The company has a 50 day moving average of $2.30 and a 200 day moving average of $2.76. The stock’s market cap is $55.61 million.

Ocera Therapeutics (NASDAQ:OCRX) last issued its earnings results on Friday, April 29th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.03. On average, equities research analysts expect that Ocera Therapeutics Inc. will post ($1.39) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Ocera Therapeutics stock. Turner Investments L.P. increased its position in shares of Ocera Therapeutics Inc. (NASDAQ:OCRX) by 29.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 673,487 shares of the biopharmaceutical company’s stock after buying an additional 152,210 shares during the period. Turner Investments L.P. owned approximately 3.28% of Ocera Therapeutics worth $2,101,000 as of its most recent filing with the SEC.

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.